HDAC9 and cancer: In a preclinical screen of different FDA-approved anti-cancer drugs, histone deacetylase (HDAC) inhibitors were found to increase expression of multiple T cell chemokines in cancer cells, macrophages and T cells, resulting in enhanced T cell infiltration and PD-1 sensitivity [121].